Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Neoplasms 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 31Cisplatin 21pembrolizumab 8Fluorouracil 6Oxaliplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Taxes 4Albumin-Bound Paclitaxel 4pemigatinib 3infigratinib 3atezolizumab 3Specimen Handling 3Radiosurgery 3Platinum 3Magnetic Resonance Spectroscopy 3Leucovorin 3Carboplatin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2trametinib 2olaparib 2ivosidenib 2derazantinib 2cobimetinib 2Trastuzumab 2Radiotherapy 2Panitumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cholangiocarcinoma × ceralasertib × Clear all
NCT03878095 2026-06-01

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
24 enrolled 12 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡